Patient and disease characteristics observed in the study
| Characteristic . | All patients . | Evaluable for toxicity . | Evaluable for efficacy . |
|---|---|---|---|
| N = 33 . | n = 25 . | n = 22 . | |
| Sex, n (%) | |||
| Female | 12 (36.4) | 8 (32) | 6 (27.3) |
| Male | 21 (63.6) | 17 (68) | 16 (72.7) |
| Age, n (%) | |||
| ≤60 y | 12 (36.4) | 7 (28) | 7 (31.8) |
| >60 y | 21 (63.6) | 18 (72) | 15 (68.2) |
| Race, n (%) | |||
| Asian | 2 (6.1) | 2 (8.0) | 2 (9.1) |
| Black | 1 (3.0) | 1 (4.0) | 1 (4.5) |
| White | 26 (79) | 19 (76) | 16 (73) |
| Unknown | 4 (12) | 3 (12) | 3 (14) |
| ECOG PS, n (%) | |||
| 0-1 | 30 (90.9) | 23 (92) | 21 (95.5) |
| ≥2 | 3 (9.1) | 2 (8.0) | 1 (4.5) |
| Stage, n (%) | |||
| I-II | 6 (18) | 6 (24) | 6 (27) |
| III-IV | 27 (82) | 19 (76) | 16 (73) |
| IPI, n (%) | |||
| 0-1 | 4 (12.1) | 4 (16) | 4 (18.2) |
| 2-3 | 16 (48.5) | 10 (40) | 10 (45.5) |
| 4-5 | 11 (33.3) | 10 (40) | 7 (31.8) |
| Unknown | 2 (6.1) | 1 (4) | 1 (4.5) |
| Disease subtype, n (%) | |||
| ABC | 11 (33.3) | 8 (32) | 7 (31.8) |
| GCB | 20 (60.6) | 16 (64) | 14 (63.6) |
| Unknown | 2 (6.1) | 1 (4) | 1 (4.5) |
| De novo DLBCL, n (%) | 18 (54.5) | 13 (52) | 11 (50) |
| Transformed LL, n (%) | 15 (45.5) | 12 (48) | 11 (50) |
| MYC aberrancy, n (%) | 13 (39.4) | 13 (52.0) | 13 (52.0) |
| DEL | 10 (30.3) | 10 (40.0) | 10 (40.0) |
| DHL | 6 (18.2) | 6 (24.0) | 6 (24.0) |
| THL | 3 (9.1) | 3 (12.0) | 3 (12.0) |
| Characteristic . | All patients . | Evaluable for toxicity . | Evaluable for efficacy . |
|---|---|---|---|
| N = 33 . | n = 25 . | n = 22 . | |
| Sex, n (%) | |||
| Female | 12 (36.4) | 8 (32) | 6 (27.3) |
| Male | 21 (63.6) | 17 (68) | 16 (72.7) |
| Age, n (%) | |||
| ≤60 y | 12 (36.4) | 7 (28) | 7 (31.8) |
| >60 y | 21 (63.6) | 18 (72) | 15 (68.2) |
| Race, n (%) | |||
| Asian | 2 (6.1) | 2 (8.0) | 2 (9.1) |
| Black | 1 (3.0) | 1 (4.0) | 1 (4.5) |
| White | 26 (79) | 19 (76) | 16 (73) |
| Unknown | 4 (12) | 3 (12) | 3 (14) |
| ECOG PS, n (%) | |||
| 0-1 | 30 (90.9) | 23 (92) | 21 (95.5) |
| ≥2 | 3 (9.1) | 2 (8.0) | 1 (4.5) |
| Stage, n (%) | |||
| I-II | 6 (18) | 6 (24) | 6 (27) |
| III-IV | 27 (82) | 19 (76) | 16 (73) |
| IPI, n (%) | |||
| 0-1 | 4 (12.1) | 4 (16) | 4 (18.2) |
| 2-3 | 16 (48.5) | 10 (40) | 10 (45.5) |
| 4-5 | 11 (33.3) | 10 (40) | 7 (31.8) |
| Unknown | 2 (6.1) | 1 (4) | 1 (4.5) |
| Disease subtype, n (%) | |||
| ABC | 11 (33.3) | 8 (32) | 7 (31.8) |
| GCB | 20 (60.6) | 16 (64) | 14 (63.6) |
| Unknown | 2 (6.1) | 1 (4) | 1 (4.5) |
| De novo DLBCL, n (%) | 18 (54.5) | 13 (52) | 11 (50) |
| Transformed LL, n (%) | 15 (45.5) | 12 (48) | 11 (50) |
| MYC aberrancy, n (%) | 13 (39.4) | 13 (52.0) | 13 (52.0) |
| DEL | 10 (30.3) | 10 (40.0) | 10 (40.0) |
| DHL | 6 (18.2) | 6 (24.0) | 6 (24.0) |
| THL | 3 (9.1) | 3 (12.0) | 3 (12.0) |
ABC, activated B cell; DEL, double-expressor lymphoma; DHL, double-hit lymphoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GCB, germinal center B-cell; LL, low-grade lymphoma; THL, triple-hit lymphoma.